Gyre Therapeutics, Inc.

Catalyst reported cash of $64.5 million as of September 30, 2021. Management said stopping MarzAA should reduce burn by approximately 40% through headcount and CRO cost reductions, and later said the company believes it has approximately 1 year of runway at the moment. No revenue, EPS, or gross margin figures were provided on this corporate update call. Forward-looking items include reporting data from the MarzAA/Crimson-1 trial to date over the next few months, submitting an IND for CB 4332 in 2022, initiating a first-in-human study next year, and nominating the next development candidate in 2022.

Nassim Usman framed the pivot as a stockholder-focused decision driven by slow MarzAA enrollment, COVID-related logistics issues, and increasing competition from prophylaxis therapies. He emphasized that MarzAA’s timeline had slipped toward late 2023 and that the company lacked the financing flexibility to continue without a partner. His tone was confident about the complement portfolio, describing it as a better long-term path for value creation and highlighting a broad opportunity set across nephrology, inflammation, ophthalmology, and other areas.

No separate CFO spoke on the call. The financial commentary came from management, which said cash was $64.5 million at September 30, 2021 and that the MarzAA shutdown should lower burn by about 40% via headcount and CRO reductions. When asked about runway, management said the company estimates roughly 1 year of cash remaining, and it also noted that it is pursuing licensing or sale options for MarzAA and DalcA.

Analysts focused on CB 4332 development, asking about how the first two CFI-deficient patients were found, the design and enrollment of the natural history study, and what data might come next year. Management explained that the ConFIrm/ConFIdence structure is meant to identify CFI-deficient patients, follow them on standard care, and support later trial comparisons; it also said the first-in-human study should be a standard safety and PK/PD trial with initial PK data expected by the end of the year. Questions also centered on MarzAA’s abrupt halt, partnership outreach, and whether the decision was driven mainly by enrollment pace; management said the key issue was that the data readout had slipped into the latter part of 2023 and that the company could not fund that path. On 2782-PEG, management said Biogen controls the news flow and that the next milestone would be entering the clinic.